- Home
- All Stock List
- NSE
- Caplin Point Laboratories Ltd Share Price
Caplin Point Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
-
9
Like
-
Share
-
Feedback
2,031.30
-19.80 (-0.97%)
-
Outperforms Index
37.63%
Return (1Y)
Beaten Nifty 500 by 30.65%
-
More Volatile
3.21%
Standard Deviation (1Y)
Higher than Nifty 500 by 2.28%
-
Consistent Performer
7/12
Months
beaten Nifty 500
-
AxisDirect View
No View
2,641
1,365
News & Announcements
-
Caplin Point Laboratories announces acquisition of Triwin Pharma S.A DE C.V
04 - Jun - 2025 12:00 | 6 days ago
Caplin Point Laboratories announced that the Company's wholly owned Subsidiary Caplin Point Far East, Hong Kong, had executed Share Purchase Agreement dated 03 June 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company. The target company is engaged in marketing and distribution of pharmaceutical products.
The acquisition was a strategic decision, as it provides a local partner in Mexico?enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with our successful strategy in other LATAM markets.
Powered by Capital Market - Live News
-
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
26 days ago
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 26 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45 453.22 11 1937.47 1694.10 14 OPM % 33.45 32.04 - 33.39 32.55 - PBDT 193.71 162.43 19 742.74 617.87 20 PBT 176.67 146.03 21 676.78 564.43 20 NP 142.57 121.59 17 536.31 457.09 17 Powered by Capital Market - Live News
-
-
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
26 days ago
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 26 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45 453.22 11 1937.47 1694.10 14 OPM % 33.45 32.04 - 33.39 32.55 - PBDT 193.71 162.43 19 742.74 617.87 20 PBT 176.67 146.03 21 676.78 564.43 20 NP 142.57 121.59 17 536.31 457.09 17 Powered by Capital Market - Live News
-
-
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Caplin Point Laboratories announces acquisition of Triwin Pharma S.A DE C.V
04 - Jun - 2025 12:00 | 6 days ago
Caplin Point Laboratories announced that the Company's wholly owned Subsidiary Caplin Point Far East, Hong Kong, had executed Share Purchase Agreement dated 03 June 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company. The target company is engaged in marketing and distribution of pharmaceutical products.
The acquisition was a strategic decision, as it provides a local partner in Mexico?enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with our successful strategy in other LATAM markets.
Powered by Capital Market - Live News
-
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
26 days ago
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 26 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45 453.22 11 1937.47 1694.10 14 OPM % 33.45 32.04 - 33.39 32.55 - PBDT 193.71 162.43 19 742.74 617.87 20 PBT 176.67 146.03 21 676.78 564.43 20 NP 142.57 121.59 17 536.31 457.09 17 Powered by Capital Market - Live News
-
-
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Caplin Point Laboratories announces acquisition of Triwin Pharma S.A DE C.V
04 - Jun - 2025 12:00 | 6 days ago
Caplin Point Laboratories announced that the Company's wholly owned Subsidiary Caplin Point Far East, Hong Kong, had executed Share Purchase Agreement dated 03 June 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company. The target company is engaged in marketing and distribution of pharmaceutical products.
The acquisition was a strategic decision, as it provides a local partner in Mexico?enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with our successful strategy in other LATAM markets.
Powered by Capital Market - Live News
-
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
26 days ago
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 26 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45 453.22 11 1937.47 1694.10 14 OPM % 33.45 32.04 - 33.39 32.55 - PBDT 193.71 162.43 19 742.74 617.87 20 PBT 176.67 146.03 21 676.78 564.43 20 NP 142.57 121.59 17 536.31 457.09 17 Powered by Capital Market - Live News
-
-
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
26 days ago
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
15 - May - 2025 12:00 | 26 days ago
Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.
For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45 453.22 11 1937.47 1694.10 14 OPM % 33.45 32.04 - 33.39 32.55 - PBDT 193.71 162.43 19 742.74 617.87 20 PBT 176.67 146.03 21 676.78 564.43 20 NP 142.57 121.59 17 536.31 457.09 17 Powered by Capital Market - Live News
-
-
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Caplin Point Laboratories Ltd has increased by 17.28% since past 3 Months
MF shareholding in Caplin Point Laboratories Ltd has increased by 63.96% since past 1 Year
FII shareholding in Caplin Point Laboratories Ltd has increased by 17.28% since past 3 Months
MF shareholding in Caplin Point Laboratories Ltd has decreased by -6.27% since past 3 Months
FII shareholding in Caplin Point Laboratories Ltd has increased by 71.57% since past 1 Year
MF shareholding in Caplin Point Laboratories Ltd has increased by 63.96% since past 1 Year
FII shareholding in Caplin Point Laboratories Ltd has increased by 17.28% since past 3 Months
MF shareholding in Caplin Point Laboratories Ltd has increased by 63.96% since past 1 Year
